Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted priority review to its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in patients aged 12 and older.
The FDA set a Prescription Drug User Fee Act target action date of 8 April 2026.
The submission is supported by results from the Phase 3 SWOG S1826 study evaluating the Opdivo and AVD regimen in both adult and paediatric populations. Bristol Myers Squibb said that this combination has the potential to become a new first-line standard of care for advanced cHL.
Classical Hodgkin lymphoma accounts for most Hodgkin lymphoma cases and remains a high-risk condition for relapse and treatment-related toxicity despite therapeutic advances.
The company highlighted the need for options that provide durable outcomes early in the treatment course and said that it plans to work with the FDA throughout the review process.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older